# Dealterms spin-offs

Framework on dealterms related to providing spin-offs access to IPR

16 March 2023

UNL working group Dealterms
Bettina Zijlstra, Joram Sjoerts, Art Bos, Roy Kolkman



#### Context

- First set of dealterms for providing spin-offs access to Intellectual Property Rights (IPR)
  - at least one of the scientific founders is committed to work fulltime for the spin-off
  - max TRL 4

#### **Early Adopters**

Erasmus MC	Radboud UMC	Wageningen University & Research	
Leiden UMC	Radboud University	TU Delft	
Leiden University	Tilburg University	TU Eindhoven	
VU Amsterdam	University of Groningen	University of Twente	
		TNO	

IPR = patents, copyright on software or designs, database-rights, know-how

#### Motivation

- No uniformity in dealterms used by Universities for transfer of IPR to spin-offs
- No transparency to the outside world
- Many opinions

#### Goal

Fair, simple & transparent dealterms with the aim to conclude deals with spin-offs faster,

in which the perspective of founders as well as investors is included:

- Founder friendly
- Attractive for investors

no limitations by universities in growth of the spin-off

to optimize impact of the research

#### Dealterms - frame

Dealterms are solely related to transfer/licensing of Intellectual Property Rights

(not investment by university, use of facilities, ... etc)

## Overview of 'tools' being used in dealmaking

Equity	Always	Often	Sometimes	Never
Fully dilutive shares	2	8	1	2
Non-dilutive shares till X MEUR investment/valuation	0	0	7	6
Non-dilutive shares	1	0	0	12
Special (voting)rights for Holding	1	1	5	6
Royalty				
Royalty on total turnover spin-off	1	1	7	4
Royalty on turnover related to IP	2	4	6	1
Cap on maximum amount of payable royalties	0	1	7	5
Option to pay off royalty obligations	0	1	5	7
Exit fee	0	2	6	5
General				
In case of patents: spin-off has to pay-back historical patent costs incurred by University	7	1	2	3
Signing fee	0	0	4	9
Milestone payments	0	3	7	3
Success fee	0	1	6	6
Transfer of ownership patent(applications)	2	5	5	1
Improvements of IP included in the deal	1	8	4	0
Does institution take equity for non-IP related contributions	2	2	7	2

### International benchmark

	US MODELS 1,2	SWISS MODELS <sup>3</sup>	QUICK LINCENSE 4	UK <sup>5</sup>
Equity	< 10% 'single digit'	Max 12% (max 9% non dilutive)		Up to 50% (Median 33%)
Dilution	Non-dilutive till X M\$ valuation	Fully dilutive		Fully dilutive
License	Royalty	Royalty	Royalty	
Exit Fee			Fixed exit Fee	
Possibility of assignment of patent to spin-off	No	No	No	Yes

Based on publicly available sources (February 2023)

### Dealmaking (spin-offs) – basic principles

- No state-aid: market-conform
  - → Benchmark with international KTO's
- Transparent, consistent & clear
- Simple
- Founder Friendly
- No hurdles for future investors
- Trust
- Stimulates growth of spin-off in favor of societal impact

#### Frame

- Dealterms are solely related to providing access to IPR
- Applicability:
  - at least one of the scientific founders is committed to work Fulltime for the spinoff
  - max TRL 4

### Dealterm Frameworks

- Equity
- Royalty
- Hybrid: Equity + Royalty

### Dealterms - general

- Spin-off is granted access to IPR in exchange for equity, royalties or combination of equity and royalties
- Starting point: exclusive license on the IPR till completion of the Milestone
- Milestone:
  - XXX k€ equity investment of YYY k€ turnover
  - Optional: technology Milestone
- Upon completion Milestone:
  - exclusive license is continued
  - option on transfer IPR after completion Milestone at no additional costs (at latest at exit)
- In case of patent(application):
  - spin-off bears costs for maintenance
  - Reimbursement of historical patent costs


Equity

### Dealterms – Equity (1)

- Fully dilutive shares
- No special rights for University/holding (except for common protection clauses)
- Inventors maintain their rights on the inventor's fee (octrooiregeling)

### Dealterms – Equity (2)

- Importance IPR for spin-off determines deal
- Dealmaking: ruler as guideline



Royalty

### Dealterms – Royalty

- Royalty on turnover related IPR % depending on sector/market
- Sublicense fee % depending on sector/market
- [optional] Milestone payment (e.g. upon certification or first commercial sales)
- [optional] Minimum annual royalty payment
- Royalty agreement stays in force at completion Milestone
- Royalty obligations stay in force at exit, option to buy-off

Hybrid

### Dealterms – Hybrid

Combination of equity and royalty

• Hybrid Royalty deal at softer conditions than full royalty deal

### **NL-Dealterms**

**Equity** 

Dilution

License

**Exit Fee** 

Possibility of assignment of patent to spin-off

Max 12,5%

Fully dilutive

Royalty

Yes

Royalty
Yes

Max 25%

Fully dilutive

Yes

### NL-Dealterms - Benchmark

	US MODELS 1,2	SWISS MODELS <sup>3</sup>	NL-HYBRID	QUICK LINCENSE 4	NL-ROYALTY	UK <sup>5</sup>	NL-EQUITY
Equity	< 10% 'single digit'	Max 12% (max 9% non dilutive)	Max 12,5%			Up to 50% (Median 33%)	Max 25%
Dilution	Non-dilutive till X M\$ valuation	Fully dilutive	Fully dilutive			Fully dilutive	Fully dilutive
License	Royalty	Royalty	Royalty	Royalty	Royalty		
Exit Fee				Fixed exit Fee			
Possibility of assignment of patent to spin-off	No	No	Yes	No	Yes	Yes	Yes

Based on publicly available sources (February 2023)